Agenda & Faculty
07:45am
Opening introduction: Ryan Fitzpatrick, CEO, MD Education
Session I: Fit AML, Chaired by: Charlie Craddock
08:00am
Research and progress in AML
Hagop Kantarjian - MD Anderson Cancer Center, Houston, Texas
08:20am
MRD and treatment decision making in Fit AML,
Felicitas Thol - Hannover Medical School, Hannover, Germany
08:40am
Genomics and treatment decision making in Fit adult AML,
Paresh Vyas - University of Oxford, UK
9:00am
Optimising front line management of Fit AML,
Alessandro Isidori - Marche Nord Hospital, Pesaro, Italy
9:20am
Which patients with high-risk AML should we transplant and how?,
Charlie Craddock - Queen Elizabeth Hospital, Birmingham, UK
9:40am
Panel Discussion
10:00am
Coffee Break
Session II: Chaired by: Naval Daver
10:20am
Optimizing frontline therapy for FLT3 mutated AML patients eligible for intensive chemotherapy,
Gesine Bug - University Hospital Frankfurt, Germany
10:40am
Treatment of APML in 2023,
Steve Knapper - Cardiff University, UK
11:00pm
Addressing inequity of outcomes and accessing patients with AML,
Pramila Krishnamurthy - King’s College Hospital NHS, Foundation Trust
11:20pm
Mechanisms of resistance and novel combinations with venetoclax based therapies in AML,
Naval Daver - MD Anderson Cancer Center, Houston, Texas
11:40pm
Panel Discussion
12:00pm
Lunch break & Networking
12:50pm
Independent educational discussion supported by Astellas
Session III: Chaired by: Alessandro Isidori
13:35pm
Research and progress in ALLL,
Hagop Kantarjian - MD Anderson Cancer Center, Houston, Texas
13:55pm
Novel approaches to treatment of TP53 mutated AML,
Emma Searle - Christie Hospital, Manchester, UK
14:15pm
Menin inhibitors,
Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA
14:35pm
Immunotherapeutic strategies in AML,
Sara Ghorashian - University College London
14:55pm
Optimising transplant outcome,
Alessandro Rambaldi - University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
15:15pm
Panel Discussion
15:35pm
Coffee break & Networking
Session IV: Chaired by: Charlie Craddock & Naval Daver
Debate: Venetoclax based regimens have an important role to play in the management of Fit adults with AML?
15:55pm
Yes to Venetoclax,
Victoria Potter - King’s College Hospital NHS Foundation Trust, London, UK
15:55pm
Yes to Venetoclax,
Alessandro Rambaldi - University of Milan and Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
16:15pm
No to Venetoclax,
Stéphane de Botton, - Tor Vergata University of Rome, Italy
16:15pm
No to Venetoclax,
Jurjen Versluis - Erasmus University, Rotterdam
16:35pm
Debate discussion
16:55pm
Optimal use of Venetoclax in unfit adults in 2023,
Jessica Altman - Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois
17:15pm
Optimal use of Venetoclax in unfit adults in 2023,
Priyanka Mehta - University Hospitals Bristol and Weston NHS Foundation Trust, UK
17:35pm
Panel discussion
17:55pm
Adjourn
Session V: Chaired by: Elias Jabbour & Anna Castleton
09:00am
Research and progress in ALL
Elias Jabbour - MD Anderson Cancer Center, Houston, Texas
09:20am
Progress and open questions in treatment of AYA ALL
Christina Peters - St. Anna Children’s Cancer Research Institute, Vienna, Austria
09:40am
Unmet needs in pediatric ALL
David O’Connor - Great Ormond Street Hospital for Children, UK
10:00am
MRD in ALL: Clinical Consequences - When and How?,
Nicola Gokbuget - University Hospital Frankfurt, Germany
10:20am
Panel Discussion
10:40am
Coffee break & networking
Session VI: Chaired by: Christina Peters & Cristina Papayannidis
11:00am
Antibodies in MRD+ ALL,
Cristina Papayannidis - Universita di Bologna Italy
11:20am
Antibodies as “Bridges to SCT” in Ph neg ALL,
Sabine Kayser - Medical Faculty Mannheim, Heidelberg University, Germany
11:40pm
How I treat Ph positive ALL in 2023,
Elias Jabbour - MD Anderson Cancer Center, Houston, Texas
12:00pm
Panel Discussion
Debate: Chaired by: Elias Jabbour, Cristina Papayannidis, Allo SCT in Ph positive ALL: for all patients?
12:20pm
Yes for all patients,
Phillippe Rousselot - Hôpital de Versailles, France
12:30pm
No for all patients,
Sabina Chiaretti - Sapienza University of Rome, Italy
12:40pm
Debate discussion
12:50pm
Lunch break & Networking
13:40pm
Independent educational discussion supported by Jazz
Session VII: Chaired by: Sabina Chiaretti & Elias Jabbour
14:25pm
Optimizing first line therapy in elderly Ph neg B- ALL,
Matthias Stelljes - Universitätsklinikum Münster, Germany
14:45pm
Genetics of Ph like ALL,
Ilaria Iacobucci - St. Jude Children’s Research Hospital, USA
15:05pm
Treatment strategies for Ph like ALL,
Anna Castleton - The Christie NHS Foundation Trust, Manchester, UK
15:25pm
Precision Medicine for T-ALL
Jan Cools - KU Leuven, Belgium, Germany
15:45pm
Panel discussion
16:05pm
Coffee break & networking
Session VIII: Chaired by: Sridhar Chaganti & Cristina Papayannidis
16:25pm
Menin inhibitors in r-KMT2A ALL,
Cristina Papayannidis - Universita di Bologna Italy
16:45pm
CAR-T in ALL: present and perspectives,
Claire Roddie - University College London, UK
17:05pm
Metabolism and ALL: therapeutic implications,
Giovanni Martinelli - IRST IRCCS, Meldola FC, Italy
17:25pm
When not to transplant in newly diagnosed ALL,
Sridhar Chaganti - Queen Elizabeth Hospital Birmingham, UK
